- An up-to-date meta-analysis shows cardiovascular (CV) and renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D), without increasing hypoglycaemia or cancer risk.
Why this matters
- Data on CV outcomes with GLP-1RAs have been inconsistent.
- Meta-analysis of 7 trials with 56,004 patients.
- Outcomes: all-cause death, composite kidney outcome (macroalbuminuria, worsening kidney function [serum creatinine doubling or ≥40% decline in estimated glomerular filtration rate], end-stage kidney disease, kidney-related death), heart failure hospitalisation.
- Funding: None.
- In pooled analysis, GLP-1RA treatment significantly reduced major adverse cardiovascular events:
- HR, 0.88 (P<.0001>
- Number needed to treat (NNT) to prevent 1 event: 75 (95% CI, 50-151).
- CV death: 0.88 (P<.0001 and>
- Fatal/nonfatal myocardial infarction: 0.91 (P=.043).
- All-cause death: 0.88 (P=.001),
- NNT to prevent 1 death: 108 (95% CI, 77-260);
- Heart failure hospitalisation: 0.91 (P=.028),
- NNT to prevent 1 event: 312 (95% CI, 165-2810); and
- Composite kidney outcome: 0.83 (95% CI, 0.78-0.89).
- No patient-level data.